Evidence map›Paper›PMID 42045577›Full record

Trial reportNature medicine2026

Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.

Ravi Thadhani, Thomas F Hiemstra, Manu Vatish, Holger Stepan, Ana Sofia Cerdeira, Jeremy Brockelsby, Tim James, Massimiliano Lia, Alissa Cornelis, Elena Krause and 23 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Glycoside fraction from pear seed functionally antagonizes sFLT-1 and restores angiogenic signaling in preeclampsia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  2. Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026
    Review
  3. Therapeutic Interventions for Preeclampsia: Integrating Placental and Maternal Perspectives.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Ravi ThadhaniCedars-Sinai Medical Center, Los Angeles, CA, USA. ravi.thadhani@csmc.edu.ORCID http://orcid.org/0000-0001-8315-9938
Thomas F HiemstraUniversity of Cambridge and Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-2115-8689
Manu VatishNuffield Department of Women's & Reproductive Health, University of Oxford and the John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0002-6012-2574
Holger StepanUniversity of Leipzig Medical Center, Leipzig, Germany.
Ana Sofia CerdeiraNuffield Department of Women's & Reproductive Health, University of Oxford and the John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0002-7643-3537
Jeremy BrockelsbyUniversity of Cambridge and Addenbrooke's Hospital, Cambridge, UK.
Tim JamesNuffield Department of Women's & Reproductive Health, University of Oxford and the John Radcliffe Hospital, Oxford, UK.ORCID http://orcid.org/0000-0002-5382-9838
Massimiliano LiaUniversity of Leipzig Medical Center, Leipzig, Germany.ORCID http://orcid.org/0000-0001-8285-3792
Alissa CornelisUniversity of Leipzig Medical Center, Leipzig, Germany.
Elena KrauseUniversity of Cologne and University Hospital Cologne, Cologne, Germany.
Martin R SpathUniversity of Cologne and University Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-1624-0055
Berthold GrüttnerUniversity of Cologne and University Hospital Cologne, Cologne, Germany.
Polina TodorovaUniversity of Cologne and University Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-4728-224X
Henning HagmannUniversity of Cologne and University Hospital Cologne, Cologne, Germany.
Kristen R YeungLiverpool Hospital and South Western Sydney Local Health District, Sydney, New South Wales, Australia.
Bei XuHeart Research Institute and University of Sydney, Sydney, New South Wales, Australia.
Scott HeffernanLiverpool Hospital and South Western Sydney Local Health District, Sydney, New South Wales, Australia.
Suzanne PearsRoyal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia.
Richard WaughRoyal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia.
John ThompsonRoyal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-2816-2496
Jim IliopoulosLiverpool Hospital and South Western Sydney Local Health District, Sydney, New South Wales, Australia.
Neroli SunderlandRoyal Prince Alfred Hospital and University of Sydney, Sydney, New South Wales, Australia.
Murray KillingsworthLiverpool Hospital and South Western Sydney Local Health District, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-6125-1183
Angela MakrisLiverpool Hospital and South Western Sydney Local Health District, Sydney, New South Wales, Australia.
Annemarie HennessySydney Local Health District and University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-5975-2843
Agnes LoCedars-Sinai Medical Center, Los Angeles, CA, USA.
Adelene Y TanAggamin Pharmaceuticals, New York, NY, USA.
Paul KussieAggamin Pharmaceuticals, New York, NY, USA.
Yuchiao ChangMassachusetts General Hospital, Boston, MA, USA.
Linda HanssensMiltenyi Biomedicine, Bergisch Gladbach, Germany.
Stefan MiltenyiMiltenyi Biomedicine, Bergisch Gladbach, Germany.
Thomas BenzingUniversity of Cologne and University Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-0512-1066
S Ananth KarumanchiCedars-Sinai Medical Center, Los Angeles, CA, USA. sananth.karumanchi@csmc.edu.ORCID http://orcid.org/0000-0002-2281-6831

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soluble Fms-like tyrosine kinase 1 (sFlt-1), a protein secreted by the placenta, plays a central role in the pathogenesis of preeclampsia-a life-threatening pregnancy complication for which no disease-specific treatment currently exists. We developed a strategy to selectively deplete circulating sFlt-1 and then conducted a single-arm, open-label trial to reduce circulating sFlt-1 in women with very preterm preeclampsia. The primary endpoints were safety and tolerability. Extracorporeal apheresis with an adsorber containing high-affinity IgG1 antibodies against sFlt-1 resulted in an approximately 50% reduction of circulating sFlt-1 levels in pregnant baboons. In women with preterm preeclampsia treated with single ascending doses (phase A, n = 7, preapheresis, mean ± s.d., sFlt-1: 15,120 ± 4,484 pg ml

Indexed as

Blood Component RemovalPre-EclampsiaVascular Endothelial Growth Factor Receptor-1AdultAnimalsFemaleGestational AgeHumansImmunoglobulin GPapioPilot ProjectsPregnancyFLT1 protein, humanImmunoglobulin GVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID42045577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.